Dr. Howard A. Fine, MD

Dr. Fine practices at Columbia University Irving Medical Center in New York, New York.

Dr. Fine's NPI, 1003166042, was assigned on September 18, 2012. Dr. Fine graduated from Icahn School Of Medicine At Mount Sinai in 1984. Dr. Fine holds New York license 266679.

Dr. Fine's primary practice is Columbia University Irving Medical Center, at 622 W 168th St, New York, NY 10032 in New York County. The practice phone is (212) 305-4920.

Dr. Fine's primary practice is Columbia University Irving Medical Center in New York, New York. Dr. Fine is also affiliated with NewYork-Presbyterian/Weill Cornell Medical Center. The medical group on file is Weill Cornell Physicians. Dmand AI also links Dr. Fine to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Fine practices, 2 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Fine's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Fine is board certified in internal medicine by the American Board of Internal Medicine. Dr. Fine is licensed in New York.

Dmand AI lists cerebrovascular disease among the conditions Dr. Fine treats.

CMS data shows 161 Medicare services from Dr. Fine across 2 procedure codes in 2024, all of them office visits, for 66 Medicare patients. Medicare paid $28,087 for them. Every service was in an office.

CMS counts 66 Medicare patients who saw Dr. Fine in 2024. The largest group is 65 to 74, with 34 patients. 74% of them have high cholesterol, and 62% have high blood pressure. 24% are also on Medicaid. Their average risk score is 1.66, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Fine's median patient age at 54, with 36% women.

In 2017, Dr. Fine wrote 33 Medicare Part D claims. Every claim was for a generic drug. They cover 2 drugs, with $716 in total drug cost. In 2016, CMS named 11 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Fine for performance year 2024, reported through an alternative payment model (APM). Dr. Fine accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Fine as offering telehealth.

Dmand AI links 154 papers to Dr. Fine, published from 2004 to 2025. 2024 was the busiest year, with 6. The most frequent topics are Brain Neoplasms, Glioma and Glioblastoma. Dr. Fine has published most often in Neuro Oncol. Dr. Fine's most frequent co-authors are Peter Mclaren Black, MD, PhD, Fabio Massaiti Iwamoto, MD and Rohan Ramakrishna, MD.

Dmand AI links Dr. Fine to 6 clinical trials, 3 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Glioblastoma, Gliosarcoma and Camurati-Engelmann Syndrome. National Cancer Institute (NCI) sponsors the most, 2.

CMS Open Payments shows 15 general payments to Dr. Fine from 3 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 78% of the total. Boehringer Ingelheim USA, Inc. paid the most, $5,950.

Dr. Fine graduated from Icahn School Of Medicine At Mount Sinai in 1984.

Dr. Fine is in network with 15 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.